- Published on 21 April 2016
A US research team recently published the results of a study showing that people with a diagnosis of hearing loss had 33% higher healthcare payments over a 1.5-year time period compared to those without hearing loss (HL).
The researchers from the Medical University of South Carolina published these findings in the journal JAMA Otolaryngology Head & Neck Surgery in early April. They examined the costs of healthcare for a matched group of privately insured middle-aged adults from 55 to 64 years of age, with and without a diagnosis of HL, reports EurekAlert.
The results were based on healthcare bills for up to 18 months of follow-up after baseline by summing costs per patient to calculate total payments for inpatient services, outpatient services, prescription medication, and cost of hearing services. The study included a total of 561,764 individuals, 50% in each group. It was found that those with a diagnosis of HL had 33% higher healthcare payments at an average of USD 14,165 versus those without this diagnosis, with costs averaging USD 10,629.
“This finding indicates that negative health-related effects of hearing loss, a condition that many consider simply an unavoidable result of aging, may manifest earlier than is generally recognized and may affect use of healthcare across the continuum of care. Studies are needed to identify the underlying factors that lead to the observed cost differences, as well as to ascertain the extent to which early and successful use of hearing aids and other hearing loss interventions modify cost differences,” say the researchers. The results are surprising because higher costs are generally thought to begin from 65 years of age and not in the middle-aged group studied here.
Source: EurekAlert; Simpson AN, et al. Higher Health Care Costs in Middle-aged US Adults With Hearing Loss. JAMA Otolaryngology Head & Neck Surgery. 2016 Apr 7
This May’s Demant forecast of 24 to 28% revenue growth in 2021 reflects a healthy hearing industry, a glad tiding underlined in this AWN interview with the group’s CEO and President Søren Nielsen.
A start-up mobile app—AudioCardio—designed to boost neuroplasticity and help sufferers of both hearing loss and tinnitus has caught the prize-picking eyes of the US business magazine, Fast Company.
In a move to boost earnings and expand in the wireless headphones segment, the Swiss hearing device group Sonova, parent of Phonak, is buying the consumer wing of the German headphone and hi-fidelity company, Sennheiser.
As automated audiometry becomes more widespread for busy clinics and teleaudiometry, Grason Stadler Inc. (GSI) interviewed Dr. Robert Margolis to discuss his automated method for testing auditory sensitivity (AMTAS).
Accompanying a better-than-expected 2021 revenue forecast by hearing giant Demant, the group’s CEO and President Søren Nielsen has underlined the strength of the hearing health market as it recovers well from the pandemic impact.
The organiser of the world’s biggest audiology event, the European Union of Hearing Aid Acousticians (EUHA), has added Instagram to its Facebook and LinkedIn social network windows.
Scientists from the University of Granada (UGR) in Spain have made a breakthrough discovery relating genes to tinnitus, specifically genes ANK2, TSC2 and AKAP9 in patients with Meniere’s disease (MD). The work opens the way to new drug treatments.
GN Hearing has launched its biggest ever upgrade in the Interton brand: Move is a new range of ten models that its maker markets as high-quality, affordable, and easy to use.[ ... ]
The Rexton brand (WS Audiology) has released a new line-up of rechargeable M-Core behind-the-ear (BTE) hearing aids, which includes the M-Core B-Li HP, a device delivering up to 61 hours of battery life on a single charge.[ ... ]
Sonova’s Unitron brand has launched a new hearing aid platform—Blu—to offer users a device adaptable to varying daily sound environments.[ ... ]